Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 89.22% is 211% above its 5-year average of -80.24%, near the high end of its 5-year range (-49885.37%–100.00%).
96.69% above its 12-month average of 45.36%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
89.22%
GROSS MARGIN AVG TTM
45.36%
GROSS MARGIN AVG 3Y
95.74%
GROSS MARGIN AVG 5Y
-80.24%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+96.69%
CURRENT VS 3Y AVG
-6.81%
CURRENT VS 5Y AVG
+211.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
+107.88%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$108.33M
Gross Margin
89.22%
TTM Avg
45.36%
3Y Avg
95.74%
5Y Avg
-80.24%
Market Cap
$109.91M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$107.45M
Gross Margin
99.54%
TTM Avg
49.77%
3Y Avg
24.89%
5Y Avg
16.59%
Market Cap
$106.83M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$109.64M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$105.15M
Gross Margin
71.67%
TTM Avg
77.09%
3Y Avg
79.04%
5Y Avg
77.65%
Market Cap
$112.13M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $108.33M | 89.22% | 45.36% | 95.74% | -80.24% |
| BGM Group Ltd. (BGM)vs › | $112.03M | 12.79% | 14.59% | 10.64% | 11.25% |
| Apyx Medical Corporation (APYX)vs › | $109.91M | 33.94% | 48.53% | 56.75% | 59.91% |
| Immunic, Inc. (IMUX)vs › | $106.73M | 0.00% | 0.00% | 0.00% | 0.00% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.45M | 99.54% | 49.77% | 24.89% | 16.59% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.83M | 83.37% | 83.81% | 82.64% | 80.50% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.64M | 0.00% | 0.00% | 0.00% | 0.00% |
| Definitive Healthcare Corp. (DH)vs › | $105.15M | 71.67% | 77.09% | 79.04% | 77.65% |
| Coya Therapeutics, Inc. (COYA)vs › | $112.13M | 99.91% | -67.10% | -31.47% | -20.98% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $105.61M | 0.00% | 0.00% | 0.00% | 2.35% |
Gross Margin
89.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 92.72% |
| 2025-12-31 | 91.33% |
| 2025-09-30 | -145.33% |
| 2025-06-30 | 88.09% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 85.23% |
| 2023-09-30 | -50.19% |
| 2023-06-30 | -422.38% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | -574.19% |
| 2022-09-30 | -305.91% |
| 2022-06-30 | -478.49% |
| 2022-03-31 | -525.20% |
| 2021-12-31 | -3050.49% |
| 2021-09-30 | -49885.37% |
| 2021-06-30 | -6581.72% |
| 2021-03-31 | -6447.55% |
| 2020-12-31 | -124.30% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
